www.alk.net
  • Patients
    • What is allergy
      • House dust mite allergy
      •  
      • Pollen allergy
      •  
      • Living with allergy
      •  
      • Socio-economic impact
      •  
    •  
    • What is allergic asthma
    •  
    • How is allergy diagnosed
    •  
    • Treating allergy
    •  
  •  
  • Healthcare Professionals
    • Treating allergy and asthma
    •  
    • Products
    •  
    • Adverse reactions
    •  
    • Initiation of treatment
    •  
    • Clinical trials
    •  
  •  
  • R&D
    • R&D pipeline
    •  
    • Understanding immunotherapy
    •  
    • Research
    •  
    • Congress activities
    •  
    • Clinical data sharing
    •  
  •  
  • Careers
    • Working at ALK
    •  
    • Vacant positions
    •  
  •  
  • Investors
    • Overview
    •  
    • Financial reporting
      • Risk management
      •  
      • Reporting standards
      •  
      • Auditors
      •  
    •  
    • Governance
      • IR policy
      •  
      • Management
      •  
      • Board of directors
      •  
      • Annual general meeting
      •  
      • Annual general meeting (DK)
      •  
    •  
    • News & Events
      • Company Releases
      •  
      • Company releases (DK)
      •  
      • Webcasts & presentations
      •  
      • Investor calendar
      •  
    •  
    • The Share
      • Dividend history
      •  
      • Analyst coverage
      •  
      • Analyst estimates
      •  
      • Shareholder information
      •  
      • Authorizations
      •  
      • ADR Programme
      •  
    •  
    • Contact IR
    •  
    • Management
    •  
    • Board of directors
    •  
    • AGM
    •  
    • AGM (DK)
    •  
    • Nyheder
    •  
    • Nyheder (EN)
    •  
  •  
  • Media
  •  
  • About
    • ALK at a glance
    •  
    • CSR
    •  
    • Production
    •  
    • Global presence
    •  
    • Organisation
    •  
    • History
    •  
    • Values
    •  
    • Owners
    •  
  •  
  • Select country
  •  
Search

Company releases

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
DateTitle
20-12-2018 7:59 EST ALK – Financial calendar for the 2019 financial year
14-12-2018 8:33 EST ALK upgrades its full-year financial outlook due to accelerated sales
27-11-2018 7:21 EST Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
13-11-2018 10:08 EST Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
9-11-2018 1:33 EST Nine-month interim report (Q3) 2018
5-11-2018 7:29 EST Release date of nine-month interim report (Q3) 2018 and audio cast
22-8-2018 14:17 UTC ALK submits registration application for tree SLIT-tablet in Europe
15-8-2018 5:37 UTC Six-month interim report (Q2) 2018
9-8-2018 10:21 CEST Release date of six-month interim report (Q2) 2018 and audio cast
4-5-2018 7:35 CEST Three-month interim report (Q1) 2018
1-5-2018 9:00 CEST Release date of three-month interim report (Q1) 2018 and audio cast
17-4-2018 12:40 CEST ALK’s partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet
11-4-2018 12:40 CEST ALK announces allergy diagnostic partnership with Rellergen in China
20-3-2018 16:19 CET Grant of share options and performance shares to members of the Board of Management and key employees
20-3-2018 15:44 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
16-3-2018 10:54 CET Articles of Association
12-3-2018 17:22 CET Annual General Meeting in ALK-Abelló A/S held on 12 March 2018
2-3-2018 16:49 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
21-2-2018 10:00 CET New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
16-2-2018 7:00 CET ALK’s partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan
13-2-2018 13:55 CET Annual General Meeting in ALK-Abelló A/S on 12 March 2018
6-2-2018 7:30 CET ALK releases its annual report 2017
30-1-2018 15:54 CET Release date of annual report 2017 and audio cast
11-1-2018 9:00 CET New Treatment for House Dust Mite (HDM) – Induced Allergic Rhinitis Now Available in US
 
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved